Study · Randomized controlled trial · n = 74 · 2012

6 results

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.

Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen E, Helqvist S, Saunamäki K, Terkelsen CJ, Schoos MM, Køber L, Clemmensen P, Treiman M, Engstrøm T

Circulation. Cardiovascular interventions10 Apr 2012Cited by 181 (Europe PMC)

PMID22496084DOI10.1161/circinterventions.112.968388PepBankPUB-22496084

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In STEMI patients with short system delay, exenatide reduced infarct mass versus placebo.
In plain wordsIn heart attack patients with short treatment delays, exenatide reduced damaged heart muscle mass compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInfarct mass with short system delay
Study
n = 74
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 minutes before intervention to 6 hours after procedureAs given in this study (human).
Measurements
Infarct mass
9 grams
Exenatide; system delay ≤132 minutes
Infarct mass
13 grams
Placebo; system delay ≤132 minutes
Source sentences
Summary
Among patients with a system delay ≤132 minutes (n=74), treatment with exenatide resulted in a smaller infarct size (9 grams [interquartile range (IQR), 4-13] versus 13 grams [IQR, 8-24], P=0.008, corresponding to 8% [IQR, 4-12] versus 11% [IQR, 7-17] of the left ventricle, P=0.015).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with STEMI and Thrombolysis In Myocardial Infarction flow 0/1 were randomly assigned to intravenous exenatide or placebo continuous infusion.
Summary · context
Study treatment was commenced 15 minutes before intervention and maintained for 6 hours after the procedure.
Report a problemFND-2249608401
02HumanRandomized controlled trialEfficacy outcome
In STEMI patients with short system delay, exenatide reduced infarct size as a percentage of the left ventricle versus placebo.
In plain wordsIn heart attack patients with short treatment delays, exenatide reduced the damaged proportion of the left ventricle compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInfarct percentage with short system delay
Study
n = 74
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 minutes before intervention to 6 hours after procedureAs given in this study (human).
Measurements
Infarct size as percent of left ventricle
8 % of left ventricle
Exenatide; system delay ≤132 minutes
Infarct size as percent of left ventricle
11 % of left ventricle
Placebo; system delay ≤132 minutes
Source sentences
Summary
Among patients with a system delay ≤132 minutes (n=74), treatment with exenatide resulted in a smaller infarct size (9 grams [interquartile range (IQR), 4-13] versus 13 grams [IQR, 8-24], P=0.008, corresponding to 8% [IQR, 4-12] versus 11% [IQR, 7-17] of the left ventricle, P=0.015).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with STEMI and Thrombolysis In Myocardial Infarction flow 0/1 were randomly assigned to intravenous exenatide or placebo continuous infusion.
Summary · context
Study treatment was commenced 15 minutes before intervention and maintained for 6 hours after the procedure.
Report a problemFND-2249608402
03HumanRandomized controlled trialEfficacy outcome
In STEMI patients with short system delay, adjusted infarct size was lower with exenatide than placebo.
In plain wordsIn heart attack patients with short delays, adjusted heart damage was lower with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseArea-at-risk-adjusted infarct size
Study
n = 74
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 minutes before intervention to 6 hours after procedureAs given in this study (human).
Source sentences
Summary
In a regression analysis adjusting for myocardial area at risk the data points of the exenatide group lay significantly lower than for the placebo group (P=0.006).
3 context sentences(design, population, supporting numbers)
Summary · context
Among patients with a system delay ≤132 minutes (n=74), treatment with exenatide resulted in a smaller infarct size (9 grams [interquartile range (IQR), 4-13] versus 13 grams [IQR, 8-24], P=0.008, corresponding to 8% [IQR, 4-12] versus 11% [IQR, 7-17] of the left ventricle, P=0.015).
Summary · context
Patients with STEMI and Thrombolysis In Myocardial Infarction flow 0/1 were randomly assigned to intravenous exenatide or placebo continuous infusion.
Summary · context
Study treatment was commenced 15 minutes before intervention and maintained for 6 hours after the procedure.
Report a problemFND-2249608403
04HumanRandomized controlled trialEfficacy outcome
In STEMI patients with long system delay, infarct mass did not differ between exenatide and placebo.
In plain wordsIn heart attack patients with long delays, damaged heart muscle mass did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeInfarct mass with long system delay
Study
n = 74
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 minutes before intervention to 6 hours after procedureAs given in this study (human).
Source sentences
Summary
In the patients with system delay >132 minutes (n=74) no difference was observed in infarct size expressed as grams (P=0.49) or percentage (P=0.46).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with STEMI and Thrombolysis In Myocardial Infarction flow 0/1 were randomly assigned to intravenous exenatide or placebo continuous infusion.
Summary · context
Study treatment was commenced 15 minutes before intervention and maintained for 6 hours after the procedure.
Report a problemFND-2249608404
05HumanRandomized controlled trialEfficacy outcome
In STEMI patients with long system delay, infarct percentage did not differ between exenatide and placebo.
In plain wordsIn heart attack patients with long delays, the damaged heart muscle percentage did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeInfarct percentage with long system delay
Study
n = 74
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 minutes before intervention to 6 hours after procedureAs given in this study (human).
Source sentences
Summary
In the patients with system delay >132 minutes (n=74) no difference was observed in infarct size expressed as grams (P=0.49) or percentage (P=0.46).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with STEMI and Thrombolysis In Myocardial Infarction flow 0/1 were randomly assigned to intravenous exenatide or placebo continuous infusion.
Summary · context
Study treatment was commenced 15 minutes before intervention and maintained for 6 hours after the procedure.
Report a problemFND-2249608405
06HumanRandomized controlled trialEfficacy outcome
In STEMI patients, system delay significantly interacted with treatment allocation for infarct size.
In plain wordsIn heart attack patients, the effect on infarct size differed with treatment delay.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableSystem delay by treatment interaction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 minutes before intervention to 6 hours after procedureAs given in this study (human).
Source sentences
Summary
There was significant interaction between system delay (less than or equal to median versus greater than median) and treatment allocation in terms of infarct size (P=0.018).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with STEMI and Thrombolysis In Myocardial Infarction flow 0/1 were randomly assigned to intravenous exenatide or placebo continuous infusion.
Summary · context
Study treatment was commenced 15 minutes before intervention and maintained for 6 hours after the procedure.
Report a problemFND-2249608406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02602600

Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

Eva Prescottn = 3319 Nov 2015 to 18 Apr 2017

Microvascular Angina

Trial page ClinicalTrials.govUpdated 11 Jul 2018

CompletedPhase 4NCT00835848

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

Copenhagen University Hospital, Rigshospitaletn = 100Jan 2009 to May 2015

Myocardial Infarction

Trial page ClinicalTrials.govUpdated 5 May 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.